GLP-1R immunoreactivity in glial cells Since earlier publications reported GLP-1R immunoreactivity in glial cells 24,25,26 , we examined potential Glp1r /GLP-1R expression by astrocytes and microglia
22 Because no head-to-head comparative trials exist, the optimal initial therapy remains uncertain, and treatment selection should be individualized based on cost, access, route of administration, and patient preference regarding route and frequency of administration (oral once per day versus oral twice per day versus subcutaneous injection every 3 months with vitamin A supplementation)
The lack of research on GLP-1 medications for endometriosis means there is no data on efficacy, optimal dosing, treatment duration, or potential interactions with standard endometriosis therapies
No dedicated cardiovascular outcomes trial (CVOT) has been completed
How does DSIP work